Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03476798 · ClinicalTrials.gov registry record · Phase 2

Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium

A Phase 2 study of Endometrial Cancer and Cervical Cancer, sponsored by University of Oklahoma.

Completed
Registry status
Phase 2
Development phase
49
Enrollment target
3
Study locations

NCT03476798 is a Phase 2 study of Endometrial Cancer and Cervical Cancer that has completed, run by University of Oklahoma. The registered enrollment target is 49 participants, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (91% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03476798, a Phase 2 study of Endometrial Cancer and Cervical Cancer, has completed, sponsored by University of Oklahoma.

COMPLETED
Registry status
Phase 2
Development phase
49 participants
Enrollment target
3
Study locations

Study Summary

This is a phase II study of rucaparib, a small molecule inhibitor poly (adenosine diphosphate \[ADP\]-ribose) polymerase (PARP), being tested in combination with bevacizumab in patients with recurrent cervical or endometrial cancer. The objective of this study is to determine the proportion of these patients who survive progression-free for at least 6 months while receiving this drug combination.

Conditions Studied

Endometrial Cancer Cervical Cancer

Interventions

  • DRUG Bevacizumab
  • DRUG Rucaparib

Study Locations (3)

Minnesota

  • University of Minnesota - Minneapolis

Oklahoma

  • Stephenson Cancer Center, University of Oklahoma Health Sciences Center - Oklahoma City

Virginia

  • University of Virginia Cancer Center - Charlottesville

Trial Details

FieldValue
Enrollment Target 49 participants
Start Date 2018-06-29
Est. Completion 2023-09-29
Phase Phase 2

Sponsor

University of Oklahoma

358 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03476798

The ClinicalTrials.gov registry entry for NCT03476798 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (91% lower). The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Endometrial Cancer appearing as the primary indexed condition, and to 2 interventions - of which Bevacizumab is the first listed.

NCT03476798 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Minnesota, Oklahoma, Virginia.

Frequently Asked Questions

What is clinical trial NCT03476798 about?

NCT03476798 is a clinical study titled "Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium". This is a phase II study of rucaparib, a small molecule inhibitor poly (adenosine diphosphate \[ADP\]-ribose) polymerase (PARP), being tested in combination with bevacizumab in patients with recurrent cervical or endometrial cancer. The objective of this study is to determine the proportion of these...

What is the current status of trial NCT03476798?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2018-06-29. Estimated completion is 2023-09-29.

What conditions does trial NCT03476798 study?

This clinical trial studies the following conditions: Endometrial Cancer, Cervical Cancer.

What interventions are being tested in trial NCT03476798?

The interventions under investigation include: Bevacizumab (DRUG), Rucaparib (DRUG).

Who is sponsoring clinical trial NCT03476798?

This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03476798 being conducted?

This trial has 3 study locations across Minnesota, Oklahoma, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Endometrial Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Endometrial Cancer

All registered trials for this condition

Cervical Cancer

All registered trials for this condition

Minnesota

All trials with a study site in Minnesota

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.